Evidence map›Paper›PMID 33846352›Full record

ArticleNPJ vaccines2021

Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection.

Mauro Di Pilato, Miguel Palomino-Segura, Ernesto Mejías-Pérez, Carmen E Gómez, Andrea Rubio-Ponce, Rocco D'Antuono, Diego Ulisse Pizzagalli, Patricia Pérez, Raphael Kfuri-Rubens, Alberto Benguría and 6 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 5 countries.

Mauro Di Pilato *Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland. mdi@mdanderson.org.ORCID http://orcid.org/0000-0003-3902-7406
Miguel Palomino-Segura *Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0003-1614-1222
Ernesto Mejías-PérezDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain.
Carmen E GómezDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain.ORCID http://orcid.org/0000-0002-5414-7935
Andrea Rubio-PonceArea of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Rocco D'AntuonoInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
Diego Ulisse PizzagalliInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
Patricia PérezInstitute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
Raphael Kfuri-RubensCenter of Integrated Protein Science Munich and Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-3256-9640
Alberto BenguríaGenomics Unit, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Ana DopazoGenomics Unit, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.ORCID http://orcid.org/0000-0002-4910-1684
Iván BallesterosArea of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Carlos Oscar S SorzanoDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain.ORCID http://orcid.org/0000-0002-9473-283X
Andrés HidalgoArea of Cell & Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Mariano Esteban *Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain. mesteban@cnb.csic.es.ORCID http://orcid.org/0000-0003-0846-2827
Santiago F Gonzalez *Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland. santiago.gonzalez@irb.usi.ch.ORCID http://orcid.org/0000-0003-4166-7664
Spanish National Centre for Cardiovascular Research · ESCentro Nacional de Biotecnología · ESUniversità della Svizzera italiana · CHCenter for Integrated Protein Science Munich · DEThe Francis Crick Institute · GBThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils are innate immune cells involved in the elimination of pathogens and can also induce adaptive immune responses. Nα and Nβ neutrophils have been described with distinct in vitro capacity to generate antigen-specific CD8 T-cell responses. However, how these cell types exert their role in vivo and how manipulation of Nβ/Nα ratio influences vaccine-mediated immune responses are not known. In this study, we find that these neutrophil subtypes show distinct migratory and motility patterns and different ability to interact with CD8 T cells in the spleen following vaccinia virus (VACV) infection. Moreover, after analysis of adhesion, inflammatory, and migration markers, we observe that Nβ neutrophils overexpress the α4β1 integrin compared to Nα. Finally, by inhibiting α4β1 integrin, we increase the Nβ/Nα ratio and enhance CD8 T-cell responses to HIV VACV-delivered antigens. These findings provide significant advancements in the comprehension of neutrophil-based control of adaptive immune system and their relevance in vaccine design.

Identifiers

PMID33846352
PMCPMC8041892
OpenAlexW3154355882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.